schizandrin a has been researched along with Fatty Liver, Nonalcoholic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Fan, S; Feng, Y; Gu, M; Huang, C | 1 |
| Jeong, MJ; Jung, UJ; Kim, SR | 1 |
2 other study(ies) available for schizandrin a and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Deoxyschizandrin ameliorates obesity and non-alcoholic fatty liver disease: Involvement of dual Farnesyl X receptor/G protein-coupled bile acid receptor 1 activation and leptin sensitization.
Topics: Animals; Bile Acids and Salts; GTP-Binding Proteins; Leptin; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Receptors, G-Protein-Coupled | 2023 |
Schizandrin A supplementation improves nonalcoholic fatty liver disease in mice fed a high-fat and high-cholesterol diet.
Topics: Animals; Antioxidants; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Cyclooctanes; Diet, High-Fat; Dietary Fats; Dietary Supplements; Fatty Acids; Fatty Acids, Nonesterified; Feces; Lignans; Lipid Metabolism; Liver; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Phytotherapy; Plant Extracts; Polycyclic Compounds; Schisandra; Triglycerides | 2019 |